

## REMARKS

In response to the restriction requirement, Applicants elect, without traverse, to prosecute claims 1, 3, 4, 11-22, 56 and 57, *i.e.*, the Group I claims. Accordingly, claims 5-10 and 24-55 are canceled as drawn to non-elected inventions. Claim 1 has been amended to introduce the subject matter claim 4 (now canceled) and also to introduce the “less than 100 amino acids” to address the unity issue with respect to Vielkind, US 6,057,116. Support for this limitation can be found, for example, in paragraphs [0127]-[0128] of the published application. Claims 2 and 23 are withdrawn pending allowance of linking claims from which they depend. See MPEP 809 and 821.04.

New claims 58-62, directed to various diagnostic agents have been added. Support for these claims can be found in paragraphs [0149]-[0155] of the published application.


With respect to the requested species election, Applicants elect targeting SEQ ID NO:30 (AGG targeting motif). Sequences that read on this election include SEQ ID NOs 5-35 and 37.

With respect to the requested therapeutic agent election, Applicants elect (KLAKLAK)<sub>2</sub> (SEQ ID NO:1). Therefore, claims 21 and 22 have been withdrawn as directed to non-elected species.

With respect to the diagnostic agent, Applicants elect hydrogen peroxidase. Therefore, new claims 60 and 61 have been withdrawn as directed to non-elected species.

Claims 1, 3, 11-20, 56, 57-59 and 62 are thus pending and under examination.

The Examiner is invited to contact the undersigned attorney at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.



Respectfully submitted,

David L. Parker

Reg. No. 32,165

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: September 20, 2007